The proposed bill, H.B. No. 2025-2026, seeks to enact section 3902.65 of the Revised Code, which mandates that health plan issuers apply prescription drug rebates to cost-sharing requirements for covered individuals. The bill defines key terms such as "health plan issuer," "price protection rebate," and "rebate," establishing a framework for how these rebates should be calculated and applied. Specifically, it requires health plan issuers to calculate a covered person's cost-sharing amount at the point of sale based on a price that reflects a 100% reduction of all rebates received in connection with the prescription drug.

Additionally, the bill includes provisions to protect the confidentiality of rebate information, stating that health plan issuers and their agents must not disclose the actual amounts of rebates received. This information is classified as confidential and not subject to public records requests. Violations of this section are deemed unfair and deceptive practices under existing insurance regulations, subjecting offenders to potential legal proceedings. Overall, the bill aims to enhance transparency and fairness in the application of prescription drug costs for consumers.